Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Validation of the two-stage laser mouse model of subretinal fibrosis and the therapeutic effect of aflibercept
Author Affiliations & Notes
  • Kyungho Park
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Hyun Woo Park
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Hee Young Lee
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Yeongyeong Kim
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Ajin Lee
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Ah Hyun Lee
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Hyuna Kim
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Larry C Park
    Naason Science Inc, Osong-eup, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Kyungho Park None; Hyun Woo Park None; Hee Young Lee None; Yeongyeong Kim None; Ajin Lee None; Ah Hyun Lee None; Hyuna Kim None; Larry Park None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 755. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kyungho Park, Hyun Woo Park, Hee Young Lee, Yeongyeong Kim, Ajin Lee, Ah Hyun Lee, Hyuna Kim, Larry C Park; Validation of the two-stage laser mouse model of subretinal fibrosis and the therapeutic effect of aflibercept. Invest. Ophthalmol. Vis. Sci. 2024;65(7):755.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Subretinal fibrosis often accompanies the neovascular form of age-related macular degeneration and leads to photoreceptor damage and serious vision loss even with therapy. We aimed to validate a model of subretinal fibrosis using two-stage laser burns and evaluate the effect of aflibercept (Eylea®), an inhibitor of vascular endothelial growth factor, in this model.

Methods : Three burns were applied by a 532 nm laser (200 mW, 100 ms, 50 μm) in each eye of male C57BL/6 mice at 7 weeks of age. 7 days later, three additional burns using the same laser settings were applied on the same positions as the initial burns. 10, 20, 30, and 40 days after the second laser burns, posterior eyecups were flat-mounted, and the neovascular and fibrotic lesions were stained with isolectin B4 (IB4) and collagen 1 (Col1). The results at each timepoint were compared with lesions induced using single laser burns (4 mice/timepoint/model).
To test the effect of aflibercept, a separate batch of mice were injected intravitreally with aflibercept (2 mg/ml) or PBS immediately after the second laser (8 mice/group). Flatmount samples were collected 10 days after the second laser for staining analysis of IB4 and Col1. Student’s t-test was used for statistical analysis.

Results : The two-stage laser model resulted in larger IB4 and Col1 staining areas compared with the single laser model at 10 (IB4: 85.4% larger in two-stage laser model, p=0.056; Col1: 89.4%, p=0.077), 30 (IB4: 95.9%, p=0.013; Col1: 96.7%, p<0.001), and 40 days (IB4: 62.8%, p=0.16; Col1: 67.2%, p=0.082) after the second laser. At 20 days after the laser, staining area of the two-stage laser lesion was lower compared with the other timepoints and comparable to single-laser lesions (IB4: -1.64%, p=0.95; Col1: -35.5%, p=0.18).
There was no significant difference in staining area of IB4 (aflibercept: 67100±6070 μm2; PBS: 66300±8310 μm2, p=0.94) and Col1 (aflibercept: 67500±6400 μm2; PBS: 71400±7090 μm2, p=0.69) between the groups treated with aflibercept and PBS 10 days after the second laser.

Conclusions : The two-stage laser mouse model produced larger fibrosis lesions compared with the single laser model. On the other hand, treatment with aflibercept did not significantly reduce subretinal fibrosis induced by the two-stage laser model. We intend to expand our investigation of subretinal fibrosis to porcine models and other targets for treatment.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×